This content is machine translated Acute myeloid leukemia The influence of time from diagnosis to treatment on overall survival Acute myeloid leukemia (AML) is often classified as an oncologic emergency leading to rapid evaluation and treatment in the hospital. Previous studies reported that time from diagnosis to treatment (TDT)...…
View Post 3 min This content is machine translated Hodgkin's lymphoma No more transplants for relapsed or refractory HL in the future? The standard treatment approach for relapsed or refractory (RR) classical Hodgkin’s lymphoma (HL) after failure of first-line treatment is second-line therapy with the aim of achieving complete remission (CR), followed...…
View Post 2 min This content is machine translated Smoldering multiple myeloma Daratumumab delays progression in smoldering multiple myeloma Smoldering multiple myeloma (SMM) is an asymptomatic premalignant precursor of active multiple myeloma (MM). Results of the presented phase III AQUILA study show that daratumumab significantly delays the progression of...…
View Post 3 min This content is machine translated Chronic lymphocytic leukemia Can CAR T-cell therapy cure CLL? An update Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL...…
View Post 3 min This content is machine translated Follicular lymphoma Addition of tafasitamab significantly improves progression-free survival The results of the phase 3 study (inMIND) indicate a new treatment option for relapsed or refractory follicular lymphoma: The addition of tafasitamab to lenalidomide and rituximab significantly prolonged progression-free...…
